Pelareorep shows promising HPV-targeted immune activity as Oncolytics Biotech advances cancer research
Oncolytics Biotech reports HPV-specific T-cell responses with pelareorep in anal cancer. See what the new immune findings mean for treatment.
Pharma & Biotech